Updated:
BrightEdge Ventures
BrightEdge is the American Cancer Society's donor-funded innovation and impact investment arm that invests in for-profit companies developing therapeutics,...
Overview
BrightEdge is the American Cancer Society's donor-funded innovation and impact investment arm that invests in for-profit companies developing therapeutics, diagnostics, medical devices, and technologies to eradicate cancer. It operates at the intersection of investment and innovation to catalyze scientific, social, and sustainable impact across the continuum of cancer care. It invests alongside top-tier life sciences and healthcare investors with a goal of generating financial returns and patient impact, with investment gains fully reinvested to scale long-term impact.
General information
Firm type
Venture Capital
Location
Region
North America
Country
United States
City
Atlanta
Corporate office
Atlanta, United States
Principals
Steve Curtis
PhD — Managing Director
Farnaz Bakhshi
PhD — Director, Innovation
Amy Berg — Principal
Philanthropy
Calum Daly — Investment Fund and Business Analyst
Alice Pomponio — managing director
Barbra Kocsis
MBA, MA — Director, Operations
Nate Macht
MBA — Investment and Innovation Senior Analyst
Michka Sharpe
PhD — Senior Associate, Investments
Jess Miciak
PhD — Associate, Investments
Bianca Scimemi — Entrepreneurs Program Manager
Josh Zail — Impact Program Manager
Ryan Margolis
PhD — Texas Accelerator Program Manager
Sector focus
Frequently asked questions
What stages does BrightEdge Ventures target?
Research records list early stage start-ups, expansion and late stage, growth, and general venture.
Where is BrightEdge Ventures headquartered?
The firm is based in Atlanta, United States.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: